ライフサイエンスコーパス: prostaglandin F2alpha

1 spectrometry as 2,3-dinor-5, 6-dihydro-8-iso-prostaglandin F2alpha.

2 Prostaglandin F2alpha (0.01 micromol/L; n=6), which redu

3 to 10(-6) mol/L), KCl (5 to 50 mmol/L), and prostaglandin F2alpha (10(-9) to 10(-6) mol/L) was compa

4 retory phospholipase A2 (sPLA2 ), and 11beta prostaglandin F2alpha (11betaPGF2alpha ), and, in a subg

5 nary metabolite of 15-F2t-isoprostane (8-iso-prostaglandin-F2alpha), 2,3-dinor-5,6-dihydro-F2t-IsoP,

6 ntake of dietary antioxidants, urinary 8-iso prostaglandin F2alpha (8-iso PGF2alpha) as a marker of o

7 In this work, 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha) was analysed in

8 ore abundant F2-isoprostanes produced, 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha).

9 ell as products of lipid peroxidation (8-iso-prostaglandin F2alpha (8-isoPF2alpha) and 4-hydroxy-2-no

10 third trimesters) and included 8-isoprostane-prostaglandin-F2alpha (8-iso-PGF2alpha), 2,3-dinor-5,6-d

11 Urinary excretion of 8-iso-prostaglandin F2alpha, an isomer of the PGG/H synthase (

12 Prostaglandin F2alpha analog plus BAB or ROCKI showed an

13 The medications evaluated included prostaglandin F2alpha analogs (PGFAs), nitric oxide-dona

14 Latanoprost, a prostaglandin F2alpha analogue, reduces IOP and is used

15 inflammation-initiating mediators including prostaglandin F2alpha and leukotriene B4 and pro-resolvi

16 dative stress was assessed by urinary 8-iso- prostaglandin F2alpha and serum soluble NOX2-derived pep

17 ssess the relationship between urinary 8-iso-prostaglandin F2alpha and serum soluble NOX2-derived pep

18 inflammation-initiating mediators (including prostaglandin F2alpha) and select proresolving pathways

19 NEAC); 2) markers of systemic (urinary 8-iso-prostaglandin-F2alpha) and muscle (carbonylated protein

20 D2 (DP)1, DP2, prostaglandin E2 (EP)1, EP4, prostaglandin F2alpha, and thromboxane A2 receptors but

21 The identification of 2, 3-dinor-5,6-dihydro-prostaglandin F2alpha as the major urinary metabolite of

22 Selective inhibition of PGF2alphaEA versus prostaglandin F2alpha biosynthesis accelerates adipogene

23 h as prostamide/prostaglandin F synthase, to prostaglandin F2alpha ethanolamide (PGF2alphaEA), of whi

24 e eye of each cat was treated topically with prostaglandin F2alpha, fluprostenol (FP receptor agonist

25 ntiated constriction of isolated arteries to prostaglandin F2alpha in proportion to the amount of PVA

26 Addition of prostaglandin F2alpha, known to limit PPARgamma activity

27 lhistamine (P < .01) and 2,3-dinor-11beta-prostaglandin F2alpha (P < .05).

28 tion of labor, prostaglandin E2 (PGE(2)) and prostaglandin F2alpha (PGF(2alpha)), are enzymatically d

29 lmonary vasoconstriction (NPV) stimulated by prostaglandin F2alpha (PGF2alpha ) and by the drug LY835

30 r prostaglandins, thromboxane A2 (TXA2 ) and prostaglandin F2alpha (PGF2alpha ), on skin microcircula

31 Thus, prostaglandin F2alpha (PGF2alpha) (FP receptor agonist),

32 We demonstrate that prostaglandin F2alpha (PGF2alpha) as well as two analogu

33 For example, prostaglandin F2alpha (PGF2alpha) causes hypertrophy of

34 The angiotensin II type I (AT1R) and the prostaglandin F2alpha (PGF2alpha) F prostanoid (FP) rece

35 the role of parasite LBs in biosynthesis of prostaglandin F2alpha (PGF2alpha) has not been investiga

36 Prostaglandin F2alpha (PGF2alpha) is a product of cycloo

37 Prostaglandin F2alpha (PGF2alpha) is an important mediat

38 alpha,20beta-dihydroxyprogesterone (DHP) and prostaglandin F2alpha (PGF2alpha) levels rise in teleost

39 hase (cyclooxygenase or COX) enzyme product, prostaglandin F2alpha (PGF2alpha), has exhibited promise

40 Prostaglandin F2alpha (PGF2alpha), which is released fro

41 licited endothelium-dependent relaxations in prostaglandin F2alpha (PGF2alpha)-contracted strips of p

42 To understand the mechanisms of prostaglandin F2alpha (PGF2alpha)-induced protein synthe

43 tion of inflammatory lipid mediators such as prostaglandin F2alpha (PGF2alpha).

44 ignaling pathways by their endogenous ligand prostaglandin F2alpha (PGF2alpha).

45 -iPs, consists of four classes of isomers of prostaglandin F2alpha (PGF2alpha).

46 so-PGF2alpha, 2,3-dinor-8-iso-PGF2alpha, and prostaglandin-F2alpha (PGF2alpha).

47 to the follicular phase using progesterone, prostaglandin F2alpha(PGF2alpha) and pregnant mare serum

48 five primary prostanoids: prostaglandin E2, prostaglandin F2alpha, prostaglandin I2, thromboxane A2,

49 pha as the major urinary metabolite of 8-iso-prostaglandin F2alpha provides the basis for the develop

50 -2'-deoxyguanosine (r = 0.53, P < 0.001) and prostaglandin F2alpha (r = 0.26, P < 0.001), and the gre

51 E2 receptors (EPs) EP1 (266) and EP4 (117), prostaglandin F2alpha receptor (FP) (61), and thromboxan

52 s, angiotensin II type I receptor (AT1R) and prostaglandin F2alpha receptor (FP), bioluminescence res

53 used to develop allosteric modulators of the prostaglandin F2alpha receptor.

54 ivo administration of the luteolytic hormone prostaglandin F2alpha resulted in an upregulation of PLI

55 s secreted inflammatory mediators, including prostaglandin F2alpha, the cytokines TNF-alpha and IL-6,

56 the oxidant stress marker isoprostane 8-epi-prostaglandin F2alpha) were identical in incubations wit